Fred Middleton, chairman and acting CEO of Novocell, said: “This composition patent is a milestone achievement for Novocell and is the culmination of extensive research that opened the door to the endoderm lineage.
“The efficient production of endoderm represents the first critical step in the creation of a renewable islet source derived from hES cells that is targeted at restoring normal glucose regulation in diabetic patients.”